| ABT |
Report |
Adjusted EPS |
BEAT |
pred ~$1.30 vs. cons $1.28 |
MEDIUM |
| ABT |
Report |
Comparable sales growth |
MISS |
pred ~9.6% vs. cons 9.85% |
MEDIUM |
| ABT |
Report |
FreeStyle Libre/CGM comparable growth |
BEAT |
pred ~11.5% vs. cons 11.0% |
LOW |
| ABT |
Guide |
Adjusted EPS guidance |
LOWER |
guide ~$5.48 midpoint vs. cons $5.50 (FY2026) |
MEDIUM |
| ABT |
Guide |
Comparable sales-growth guidance |
UNCHANGED |
guide ~7.0% midpoint vs. cons 7.0% (FY2026) |
MEDIUM |
| ABT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.4% |
— |
MEDIUM |
| ABT |
Return |
5-day cumulative residual |
+0.9% (FADE) |
A ~$0.02 Q2 EPS beat is unlikely to flow through because FY2026 EPS guidance of ~$5.48 remains below consensus of $5.50, implying second-half EPS of roughly $3.03 versus Street expectations near $3.05; improving Libre and Nutrition trends support an initial relief rally, but limited upward revisions drive a partial fade. |
MEDIUM |